Posted by Michael Wonder on 27 Oct 2017
Shire receives European approval for label extension of Firazyr (icatibant injection) for the symptomatic treatment of acute hereditary angioedema attacks in paediatric patients
26 October 2017 - Firazyr is the first and only subcutaneous treatment in Europe for acute HAE attacks approved for children aged 2 years and older
Shire announced today that the European Commission has approved a label extension granting a new indication for Firazyr (icatibant injection), broadening its use to adolescents and children aged 2 years and older, with hereditary angioedema caused by C1-esterase-inhibitor deficiency.
Firazyr has been approved in the European Union since 2008 for symptomatic treatment of acute attacks of HAE in adults with C1-INH deficiency.
